Skip to main content

Research Repository

Advanced Search

All Outputs (4)

Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer? (2024)
Journal Article
Mohamed, E., Fletcher, D., Hart, S., & Guinn, B.-A. (2024). Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?. Onco, 4(2), 87-100. https://doi.org/10.3390/onco4020008

Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors and their discovery rate has been increasing due to enhanced performance of chest CT scans but more than 90% are non-malignant causi... Read More about Can tumour antigens act as biomarkers for the early detection of non-small cell lung cancer?.

Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis (2024)
Journal Article
Guillen-Guio, B., Paynton, M. L., Allen, R. J., Chin, D. P., Donoghue, L. J., Stockwell, A., …Hollox, E. J. (2024). Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis. ERJ Open Research, 10(1), https://doi.org/10.1183/23120541.00553-2023

Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia marked by progressive lung fibrosis and a poor prognosis. Recent studies have highlighted the potential role of infection in the pathogenesis of IPF, and a prior ass... Read More about Association study of human leukocyte antigen variants and idiopathic pulmonary fibrosis.

Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK (2024)
Journal Article
Dixon, G., Hague, S., Mulholland, S., Adamali, H., Khin, A. M. N., Thould, H., …Barratt, S. L. (2024). Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Research, 10(1), Article 00529-2023. https://doi.org/10.1183/23120541.00529-2023

Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in... Read More about Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK.